Trade Summary

6 days ago, Blum Robert I, serving as Pres, CEO at Cytokinetics Inc (CYTK), sold 36,601 shares at $62.15 per share, for a total transaction value of $2,274,752.00. Following this transaction, Blum Robert I now holds 434,496 shares of CYTK.

This sale represents a 8.00% decrease in Blum Robert I's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Tuesday, March 17, 2026 and publicly disclosed via SEC Form 4 filing on Wednesday, March 18, 2026, 1 day after the trade was made.

Cytokinetics Inc operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.